Overview

Imatinib in KIT-negative Systemic Mastocytosis

Status:
Completed

Trial end date:
2015-08-01

Target enrollment:

Participant gender:

Summary

The aim of this study is to evaluate the efficacy in terms of clinical and biological response rates of Imatinib Mesylate therapy in patients with systemic mastocytosis lacking KIT mutations.

Phase:

Phase 4

Details

Lead Sponsor:

Hospital Virgen de la Salud

Treatments:

Imatinib Mesylate